Autopsy report · NCT04746924

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

“This decision was conducted by the sponsor based on lack of efficacy and not driven by safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 4 years 10 months before it stopped.
• 669 participants enrolled.
• Results were posted on the registry 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

BeiGene

Sponsor type

Industry

Conditions

Non-small Cell Lung Cancer; NSCLC

Interventions

Tislelizumab; Ociperlimab; Pembrolizumab; Placebo

Participants

669

Sites

218

Countries

Argentina, Australia, Brazil, China, France, Georgia, Germany, Italy, Japan, Netherlands, Poland, Russia and more

Trials that died the same way

• A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
  “Due to sponsor decision, not for efficacy or safety reasons.” (81% match in meaning)
• Long-Chain Fatty Acid Oxidation Disorders Online Disease Monitoring Program
  “Sponsor decision not related to safety concerns” (80% match in meaning)
• Trans Sodium Crocetinate (TSC) Study of Intra-tumoral Oxygen Concentration, Safety, and Pharmacokinetics in Patients With High Grade Glioma
  “Sponsor business decision, not based on safety or efficacy data.” (80% match in meaning)
• REGENETEN™ Bioinductive Implant System in Full-thickness Tears
  “Sponsor decision not related to safety.” (80% match in meaning)
• Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
  “This was a sponsor decision and was not a consequence of any safety concern” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.